Medical Management of Breast Cancer: A Comprehensive Guide
At a Glance
- Sample Required: Blood or saliva for genetic testing (BRCA1/BRCA2, NGS panel)
- Fasting Rules: None required for genetic testing
- Turnaround Time (TAT): 7–14 business days for comprehensive genomic profiling
- Base Cost: [Insert Current 2026 Price]
Breast cancer management has evolved significantly with the advent of precision medicine. The optimal treatment plan is no longer a one-size-fits-all approach but is tailored to the tumor's molecular profile, stage, and the patient's overall health. This guide provides an authoritative overview of current medical management strategies, including the critical role of genetic testing in guiding therapy.
Understanding Breast Cancer Subtypes
Breast cancer is a heterogeneous disease. Treatment decisions hinge on the expression of hormone receptors (ER/PR), HER2 amplification, and genomic markers. The following table summarizes the main subtypes and their therapeutic implications.
| Subtype | Molecular Marker | First-Line Systemic Therapy |
|---|---|---|
| Luminal A | ER+ / PR+ / HER2- | Endocrine therapy (e.g., tamoxifen, aromatase inhibitors) |
| Luminal B | ER+ / PR+ / HER2- (with high Ki-67) | Endocrine therapy ± chemotherapy |
| HER2-enriched | HER2+ (ER/PR variable) | Anti-HER2 therapy (e.g., trastuzumab, pertuzumab) + chemotherapy |
| Triple-negative | ER- / PR- / HER2- | Chemotherapy, immunotherapy (e.g., pembrolizumab) in PD-L1+ |
Treatment Modalities
The mainstay of breast cancer treatment includes local therapies (surgery and radiation) and systemic therapies (chemotherapy, endocrine therapy, targeted therapy, and immunotherapy). The selection and sequence depend on stage, subtype, and genomic profiling.
Surgical Interventions
Surgery remains the primary local treatment for early-stage breast cancer. Options include:
- Lumpectomy (breast-conserving surgery): Removal of the tumor and a small margin of healthy tissue, typically followed by radiation therapy.
- Mastectomy: Removal of the entire breast, often with sentinel lymph node biopsy or axillary dissection when indicated.
Radiation Therapy
High-energy radiation is used to eliminate residual cancer cells post-surgery or as definitive treatment for inoperable early-stage tumors. Modern techniques like intensity-modulated radiation therapy (IMRT) minimize damage to surrounding tissues.
Chemotherapy
Cytotoxic drugs are used in cases of high-risk or metastatic disease. Neoadjuvant chemotherapy may shrink tumors before surgery, while adjuvant chemotherapy reduces recurrence risk. Genomic assays (e.g., Oncotype DX) help determine who truly benefits.
Endocrine (Hormone) Therapy
For hormone receptor-positive tumors, endocrine therapy blocks estrogen/progesterone signaling. Options include selective estrogen receptor modulators (SERMs), aromatase inhibitors, and ovarian suppression in premenopausal women.
Targeted Therapy
HER2-positive breast cancer is treated with monoclonal antibodies (trastuzumab, pertuzumab) and antibody-drug conjugates (e.g., T-DM1). Additionally, CDK4/6 inhibitors (palbociclib, ribociclib) are used in metastatic ER+ disease.
Immunotherapy
Immune checkpoint inhibitors (e.g., pembrolizumab) are approved for triple-negative breast cancer with PD-L1 expression, either alone or in combination with chemotherapy.
Role of Genetic Testing in Breast Cancer Management
Genetic testing plays a pivotal role in both hereditary risk assessment and somatic tumor profiling. At DNA Labs India, we utilize Next-Generation Sequencing (NGS) and Whole Exome Sequencing (WES) to identify actionable mutations.
- Germline testing: Detects inherited BRCA1/BRCA2 mutations, guiding prophylactic surgery and PARP inhibitor therapy.
- Somatic testing: Identifies mutations in the tumor (e.g., PIK3CA, ESR1) that inform targeted treatment choices.
- Pharmacogenomics: Predicts response to chemotherapy agents, reducing adverse effects.
Our laboratory is ISO 9001 certified, ensuring high-quality, reliable results. Genetic counseling is recommended before and after testing.
Multidisciplinary Approach
The optimal treatment plan is determined by a tumor board comprising medical oncologists, surgical oncologists, radiation oncologists, pathologists, radiologists, and genetic counselors. This collaborative approach ensures personalized, evidence-based care.
Frequently Asked Questions
What is the turnaround time for genetic testing?
Typical TAT for comprehensive genomic profiling is 7–14 business days.
Is fasting required?
No fasting is required for genetic testing.
Written by: Dr. Ananya Sharma, MBBS, MD (Internal Medicine)
Medically Reviewed by: Dr. Rajesh Kumar, DM (Medical Oncology)
Last Updated: March 2026